AtriCure shares surged 6.2% to close at $28.80 in the last trading session on heavy volume. The rally followed the company's presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated its target of reaching $1 billion in revenue by 2030 and highlighted the market-expanding potential of its BoxX-NoAF and LeAAPS clinical trials. Investors also reacted to news of accelerated enrollment in the BoxX-NoAF trial, which could significantly broaden the company's addressable market if outcomes are positive. The stock currently carries a Zacks Rank of 3, or Hold.
AtriCure IncManagement reaffirmed $1B revenue goal by 2030 and highlighted market-expanding potential of clinical trials, with accelerated enrollment in BoxX-NoAF trial.
Quidel Corporation